Are exosomes the same as extracellular vesicles?

Exosomes are a subset of extracellular vesicles (EVs). Specifically, they are EVs with a diameter of roughly 30 to 150 nanometers that originate from endosomes inside cells. Other EV types include microvesicles and apoptotic bodies. In practice, the boundaries are not always cleanly separable with current isolation methods, and the terms are sometimes used interchangeably in research.

Why does the FDA consider exosomes used after microneedling to be systemic rather than topical?

Microneedling creates hundreds of micro-channels in the skin. When exosomes are applied immediately after, they can penetrate through those channels and potentially reach the bloodstream rather than remaining in the superficial skin layers. The FDA treats this pathway differently from standard topical application and requires clinical safety data appropriate for systemic exposure.

Where is exosome research heading?

Multiple Phase I and Phase II clinical trials are underway with IND clearance from the FDA. Active research areas include wound healing, alopecia, atopic dermatitis, and graft-versus-host disease. These trials are building the evidence base that a regulatory pathway would require. Approval timelines are difficult to predict but are measured in years, not months.

Exosome Skincare Is Growing Fast. FDA Has Approved Zero Products.

Exosomes are nano-sized particles secreted by cells, carrying proteins, RNA, lipids, and other signaling molecules. In skin science, they have attracted significant research attention for their potential role in tissue regeneration, collagen synthesis stimulation, and inflammation modulation. The consumer market has run ahead of that research.

As of 2026, the FDA has not approved a single exosome-based product, topical or injectable.

The warning letter record

Between 2022 and 2025, the FDA issued more than six warning letters to manufacturers marketing exosome products in the United States. The regulatory concerns fall into two main categories.

Unapproved biologics: The FDA classifies exosomes under the category of cellular and gene therapy products. Marketing them for therapeutic purposes without clinical safety data and regulatory clearance constitutes selling an unapproved drug, regardless of how the product is labeled on shelf.

The microneedling problem: Topical application of a cosmetic ingredient is subject to less stringent oversight than a drug. But when exosomes are applied to skin immediately after microneedling, the FDA’s position is that this constitutes systemic administration. Microneedling creates micro-channels that extend below the epidermis, and substances applied through those channels can reach the bloodstream. The FDA requires drug-level safety evidence for this delivery route.

What an exosome label does not mean

A product with “exosome” on its label is making no regulatory claim that has been verified by any health authority. Several practical considerations apply.

Isolation quality varies widely: High-purity exosomes require precision manufacturing, typically involving ultracentrifugation or size-exclusion chromatography. The concentration and purity of exosome preparations in cosmetic-grade products can differ substantially from those used in clinical trials.

Stability during distribution: Exosomes carry temperature-sensitive proteins and RNA. Whether the active content survives from manufacturing to consumer use is a legitimate question that most products do not address with transparency.

Mechanism in topical application: Even assuming high-quality exosomes in a well-formulated serum, how they interact with intact skin barriers, as opposed to tissue in a laboratory wound model, is not established at the clinical level.

The research direction is genuine

The FDA’s current posture does not represent a judgment that exosome biology is unimportant. Multiple Phase I and Phase II clinical trials are proceeding with IND (Investigational New Drug) clearance. Wound healing, hair loss, atopic dermatitis, and graft-versus-host disease are among the most active investigation areas.

The gap is between what laboratory data and early trial results suggest is possible, and what a completed clinical development program with Phase III safety data would demonstrate. That gap is not unusual for a technology at this stage. It simply means the consumer market is operating without the kind of evidence base that normally precedes commercialization at this scale.

The regulatory framework will eventually catch up to the science. Phase II results in wound healing and alopecia have been encouraging enough that larger trials are proceeding. What the timeline looks like depends on trial completion and FDA review, measured in years.

A practical lens for consumers

For anyone currently using exosome products or considering exosome treatments, a few questions are worth resolving before spending.

First: is the exosome source plant-derived or stem cell-derived? The research base and risk profiles differ. Plant-derived EVs (as in centella EV serums) are subject to different regulatory treatment than human or animal cell-derived exosomes intended for biological activity.

Second: is microneedling involved? If yes, the safety calculus changes. This is not necessarily a reason to avoid, but it is a reason to ask the provider what preparation they are using, where it is sourced, and what sterility standards it meets.

Third: what claims is the manufacturer making? Mechanism claims with published data behind them are different from marketing language that borrows the research vocabulary without the supporting trials.

Exosome science is moving forward. The consumer products currently using that language are, for the most part, ahead of the evidence.

Source: Unicorn Bioscience / FDA